|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||93.41 - 93.73|
|52-week range||88.75 - 112.65|
|Beta (5Y monthly)||0.46|
|PE ratio (TTM)||16.97|
|Forward dividend & yield||3.86 (4.12%)|
|Ex-dividend date||05 May 2021|
|1y target est||N/A|
New England Journal of Medicine publishes positive Phase 3 Dupixent® (dupilumab) results in children with moderate-to-severe asthma Dupixent significantly reduced severe asthma attacks and improved lung function and asthma control in children aged 6 to 11 years with uncontrolled moderate-to-severe asthmaPublished results reinforce well-established safety profile of DupixentPositive data formed the basis for FDA approval of Dupixent in these patients with certain types of moderate-to-severe asthm
Glaxo (GSK) and Medicago's plant-based vaccine achieves more than 70% efficacy rate against COVID-19 and its major variants.
The EMA accepts Sanofi's (SNY) regulatory submission seeking approval for olipudase alfa, a potential treatment for acid sphingomyelinase deficiency.